

Vimta Labs Limited

Registered Office
142, IDA Phase II, Cherlapally
Hyderabad-500 051, Telangana, India
T : +91 40 2726 4141
F : +91 40 2726 3657



VLL\SE\058\2024-25
Date: 08.11.2024

Listing Centre
B S E Limited
P J Towers, Dalal Street
Mumbai: 400001
Scrip Code No.524394

Asst Vice President
National Stock Exchange of India Limited
“Exchange Plaza”, Bandra
Kurla Complex, Bandra (E)
Mumbai – 400051
Trading Symbol: VIMTALABS

Dear Sir/Madam,

Subject – Press Release – Unaudited Financial Results – 30th September 2024.

Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find attached the press release in connection with an announcement of unaudited Standalone and Consolidated Financial Results for the 2nd Quarter/ Half Year ended 30th September 2024.

This is for your information and records.

Thanking you,

Yours faithfully,
for VIMTA LABS LIMITED

Sujani Vasireddi
Company Secretary

Attachments: as above.



Vimta Labs Limited Reports Q2 & H1 FY25 Results

Q2 FY25 Total Income at Rs. 854 Mn, EBITDA margins at 35.8%; PAT margin at 19.9%

Hyderabad, November 8, 2024: Vimta Labs Limited (VIMTA) (BSE: 524394, NSE: VIMTALABS), India's leading Contract Research and Testing Organisation, has announced its financial results for the quarter and half year ended September 30, 2024.

Consolidated Financial Results – Q2 & H1 FY25:

Particulars (Rs. Mn)	Q2FY25	Q1FY25	QoQ	Q2FY24	YoY	H1 FY25	H1FY24	YoY
Total Income	854	756	13.0%	676	26.4%	1,610	1,439	11.9%
EBITDA (including other income)	306	266	14.9%	194	57.3%	572	468	22.1%
EBITDA Margin	35.8%	35.2%	59 bps	28.8%	704 bps	35.5%	32.6%	298 bps
PAT (continued operations)	170	139	22.4%	81	109.9%	309	226	36.8%
PAT Margin	19.9%	18.4%	153 bps	12.0%	793 bps	19.2%	15.7%	350 bps
Basic EPS	7.7	6.3	22.2%	3.7	108.1%	13.9	10.2	36.3%

Note: Vimta Labs sold its Diagnostic and Pathological services business to Thyrocare Technologies, as announced on August 30, 2024, with the transfer completed on October 11, 2024. Previous period figures for P&L have been regrouped to ensure comparability with the current period

Commenting on results, Ms. Harita Vasireddi, Managing Director, Vimta Labs Limited, said: "We are pleased to report a strong operational performance for Q2FY25, with revenues of ₹854 mn, reflecting a 26.4% YoY growth. Our EBITDA rose by 57.3% YoY, and net profit surged by 109.9%. This performance was primarily driven by our pharmaceutical services, which continue to lead the business.

As stated in our August 30, 2024, press release, Vimta Labs has divested the Diagnostic and Pathological services business to Thyrocare Technologies. This decision allows us to sharpen our focus on core services and optimize resources for sustained growth, resulting in a significant improvement in our EBITDA margins, which now exceed 35%, up from the previous range of 23% to 30%.

Looking ahead, our Pharmaceutical services continue to show promising growth, and we anticipate that our food testing services will also contribute to growth in coming quarters. We are also expanding our electrical and electronics testing capabilities and preparing to commission a new facility in couple of quarters. We remain committed to driving sustainable and impactful growth for our investors."

Key Result Highlights for the Q2 & H1 FY25 (Consolidated)^:

Q2 FY25

- ✓ Total Income for Q2 FY25 was at Rs. 854 Mn
- ✓ EBITDA for Q2 FY25 was Rs. 306 Mn; EBITDA margin was at 35.8%
- ✓ PBT for Q2 FY25 was at Rs. 219 Mn
- ✓ Q2 FY25 PAT* was at Rs. 170 Mn; PAT margin was at 19.9%

- ✓ Basic EPS in Q2 FY25 was Rs. 7.7

H1 FY25

- ✓ Total Income for H1 FY25 was at Rs. 1,610 Mn
- ✓ EBITDA for H1 FY25 was Rs. 572 Mn; EBITDA margin was at 35.5%
- ✓ PBT for H1 FY25 was at Rs. 401 Mn
- ✓ H1 FY25 PAT* was at Rs. 309 Mn; PAT margin was at 19.2%
- ✓ Basic EPS in H1 FY25 was Rs. 13.9
- ✓ Total Debt as of 30th September 2024 stood at Rs. 116 Mn
- ✓ Cash and Cash equivalents including bank balance stood at Rs. 278 Mn as of 30th September 2024

Note:

* Profit/(Loss) for the period from continuing operations

^ Vimta Labs sold its Diagnostic and Pathological services business to Thyrocare Technologies, as announced on August 30, 2024, with the transfer completed on October 11, 2024. Previous period figures for P&L have been regrouped to ensure comparability with the current period

ABOUT VIMTA LABS LIMITED:

Founded in 1984 with headquarters in Hyderabad, India, VIMTA LABS LTD., is a leading contract research and testing organization, providing food, agri, bio/pharmaceutical, medical device, speciality chemical, and electronics companies an integrated scientific, technical, and regulatory expertise to support all stages of product development and manufacturing process. Vimta also provides environmental assessments and testing services.

CAUTIONARY STATEMENT:

This press release may contain certain forward-looking statements. Any forward-looking statement applies only on the date of this press release. By their nature, forward-looking statements are subject to a number of known and unknown risks and uncertainties that may or may not occur in the future and as a result of which the actual results and performance may differ substantially from the expected future results or performance expressed or implied in the forward-looking statements. No warranties or representations are made as to the accuracy, achievement, or reasonableness of such statements, estimates or projections, and Vimta Labs Limited has no obligation to update any such information or to correct any inaccuracies herein or omission here from which may become apparent.

For details, please contact:

Investor Relations at Vimta Labs Narahai Naidu Dodda, CFO Narahai.Dodda@vimta.com Ernst & Young Mr. Siddesh Chawan Siddesh.Chawan@in.ey.com Mr. Advait Bhadekar Advait.bhadekar@in.ey.com	Registered Office Plot Number 142, IDA Phase 2, Cherlapally, Hyderabad Telangana, India. 500051 CIN: L24110TG1990PLC011977 ISIN: INE579C01029 NSE Code: VIMTALABS BSE CODE: 524394 Website: www.vimta.com
--	--